Rhythm gets sec­ond OK for ge­net­ic obe­si­ty drug Im­civree, swings in­to roy­al­ty deal

An­oth­er OK, an­oth­er 2,000 po­ten­tial pa­tients.

On Thurs­day, Rhythm Phar­ma­ceu­ti­cals re­ceived its sec­ond FDA green light for its obe­si­ty man­age­ment drug for those with ul­tra …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER